| Old Articles: <Older 5131-5140 Newer> |
|---|
 |
The Motley Fool
September 23, 2008
Brian Orelli |
Extended Look at an Extended-Release Drug The FDA is still investigating Teva's generic Wellbutrin XL.   |
The Motley Fool
September 23, 2008
Brian Lawler |
Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released. |
The Motley Fool
September 22, 2008
Brian Orelli |
Ouch, That's Gotta Hurt! Acupuncture beats Wyeth's Effexor in stopping hot flashes. |
The Motley Fool
September 22, 2008
Brian Orelli |
Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out? |
The Motley Fool
September 22, 2008
Brian Lawler |
Why Bristol-Myers Won't Pull Its ImClone Bid Bristol-Myers might drop its cash bid of $60 per share to acquire longtime partner ImClone Systems. |
The Motley Fool
September 22, 2008
Brian Orelli |
Syneron Irons Out Some Wrinkles The aesthetic device maker gets a new product approved in Europe. |
Fast Company
October 2008
Peter Carbonara |
Geisinger Health System's Plan to Fix America's Health Care How a small network of hospitals in Pennsylvania is defying convention, cutting costs, and improving health care. |
Chemistry World
September 19, 2008
John Bonner |
Filling the antibiotic gap Resistance to currently available antibacterial drugs is causing growing concern among doctors who find themselves unable to treat common infections |
The Motley Fool
September 19, 2008
Brian Orelli |
Skinning the Competition J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel. |
The Motley Fool
September 19, 2008
Brian Lawler |
FDA Tells Gilead to Take 1 More Step There's a small consolation prize for Gilead Sciences in this rejection from the FDA. |
| <Older 5131-5140 Newer> Return to current articles. |
